 Pharmaceutical Assets Include Companys Non-Opioid Anti-inflammatory Compound KLS-13019 to Treat Chemotherapy Induced Peripheral Neuropathy CIPN Companys Strategy is to Utilize the Phase 2 Study Grant Funds to Complete Preclinical Studies in CIPN and Ready the Company to Begin FDA Phase 1 Human Clinical Trials DOYLESTOWN, PA ACCESSWIRE September 28, 2021 Neuropathix, Inc. Neuropathix or the Company OTCQB:NPTX, a socially responsible pain management life sciences company, today announces that its wholly owned subsidiary, Kannalife Sciences, Inc. has received a notice of award from the National Institute of Neurological Disorders and Stroke NINDS of the National Institutes of Health NIH for a 2.97 million Phase 2 STTR Study Grant. The three-year STTR Study Grant is funded through the NIH HEAL Initiative Helping End Addiction Long-term for Development of Therapies and Technologies Directed at Enhanced Pain Management and will provide funding specifically in the Development of KLS-13019 for Neuropathic Pain. 